Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07361029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

Study acronym: CD19 CART CELL
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a Phase Ia, open label, dose finding single center trial designed to evaluate the maximum tolerated dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CD19 CAR T cells targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in adults (age 18 - 75) with relapsed/refractory acute lymphoblastic leukemia (ALL).
Trial Details
NCT Number NCT07361029
Lead Sponsor King Faisal Specialist Hospital & Research Center
Collaborators: Miltenyi Biomedicine GmbH
Conditions
(from sponsor)		 Relapsed Refractory Acute Lymphoblastic Leukemia
Related terms Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov